• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective.胰腺癌中 miRNA 的异常表观遗传学修饰:系统生物学视角。
Epigenomics. 2011 Dec;3(6):747-59. doi: 10.2217/epi.11.97.
2
Epigenetic Regulation of the Hippocampus, with Special Reference to Radiation Exposure.海马体的表观遗传调控,特别参考辐射暴露。
Int J Mol Sci. 2020 Dec 14;21(24):9514. doi: 10.3390/ijms21249514.
3
Interplay between microRNAs and the epigenetic machinery: an intricate network.微小RNA与表观遗传机制之间的相互作用:一个复杂的网络。
Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):694-701. doi: 10.1016/j.bbagrm.2010.05.005. Epub 2010 May 20.
4
Epigenetics of kidney cancer and bladder cancer.肾癌和膀胱癌的表观遗传学。
Epigenomics. 2011 Feb;3(1):19-34. doi: 10.2217/epi.10.64.
5
Epigenetics and miRNAs in human cancer.人类癌症中的表观遗传学和 miRNA。
Adv Genet. 2010;70:87-99. doi: 10.1016/B978-0-12-380866-0.60004-6.
6
Investigating the regulatory role of miRNAs as silent conductors in the management of pathogenesis and therapeutic resistance of pancreatic cancer.探讨 miRNAs 作为沉默导体在调控胰腺癌发病机制和治疗抵抗中的作用。
Pathol Res Pract. 2023 Nov;251:154855. doi: 10.1016/j.prp.2023.154855. Epub 2023 Oct 5.
7
Epigenetic studies in human diseases.人类疾病中的表观遗传学研究。
Folia Biol (Praha). 2010;56(3):83-96.
8
Epigenetic Regulations in the Pathogenesis of Periodontitis.牙周炎发病机制中的表观遗传调控
Curr Stem Cell Res Ther. 2018;13(2):144-150. doi: 10.2174/1574888X12666170718161740.
9
Prospects of miRNA-based therapy for pancreatic cancer.基于 microRNA 的胰腺癌治疗前景。
Curr Drug Targets. 2013 Sep;14(10):1101-9. doi: 10.2174/13894501113149990181.
10
Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives.微小 RNA 与胰腺癌化疗耐药的相关性:现有知识、新见解和未来展望。
Pathol Res Pract. 2022 Aug;236:153982. doi: 10.1016/j.prp.2022.153982. Epub 2022 Jun 15.

引用本文的文献

1
Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.基于靶向纳米颗粒的胰腺癌诊断与治疗方案
Cancers (Basel). 2024 Apr 20;16(8):1589. doi: 10.3390/cancers16081589.
2
Longitudinal evaluation of whole blood miRNA expression in firefighters.消防员全血 miRNA 表达的纵向评估。
J Expo Sci Environ Epidemiol. 2021 Sep;31(5):900-912. doi: 10.1038/s41370-021-00306-8. Epub 2021 Feb 18.
3
NO and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential.一氧化氮与胰腺癌:具有治疗潜力的复杂相互作用
Antioxid Redox Signal. 2017 Jun 10;26(17):1000-1008. doi: 10.1089/ars.2016.6809. Epub 2016 Sep 22.
4
MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer.微小RNA表达及其在胆囊癌诊断和治疗中的意义。
Oncotarget. 2015 Jun 10;6(16):13914-21. doi: 10.18632/oncotarget.4227.
5
Regulation of microRNAs by epigenetics and their interplay involved in cancer.表观遗传学对微小RNA的调控及其在癌症中的相互作用。
J Exp Clin Cancer Res. 2013 Nov 22;32(1):96. doi: 10.1186/1756-9966-32-96.
6
Nuclear export mediated regulation of microRNAs: potential target for drug intervention.核输出介导的 microRNAs 调控:药物干预的潜在靶点。
Curr Drug Targets. 2013 Sep;14(10):1094-100. doi: 10.2174/1389450111314100002.
7
Identifying Biomarkers and Drug Targets Using Systems Biology Approaches for Pancreatic Cancer.使用系统生物学方法鉴定胰腺癌的生物标志物和药物靶点。
Pancreat Disord Ther. 2012 Dec 6;2(4):1000e128. doi: 10.4172/2165-7092.1000e128.

本文引用的文献

1
MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia.MicroRNA-193b 调控 c-Kit 原癌基因并抑制急性髓系白血病细胞增殖。
Leuk Res. 2011 Sep;35(9):1226-32. doi: 10.1016/j.leukres.2011.06.010. Epub 2011 Jul 2.
2
Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development.启动子甲基化下调 miR-132 促进胰腺癌的发展。
Carcinogenesis. 2011 Aug;32(8):1183-9. doi: 10.1093/carcin/bgr105. Epub 2011 Jun 10.
3
Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors.MDM2抑制剂与奥沙利铂联合使用的网络建模揭示了野生型p53实体瘤中的生物学协同作用。
Oncotarget. 2011 May;2(5):378-92. doi: 10.18632/oncotarget.269.
4
Pancreatic cancer.胰腺癌。
Lancet. 2011 Aug 13;378(9791):607-20. doi: 10.1016/S0140-6736(10)62307-0. Epub 2011 May 26.
5
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.微小 RNA(miRNAs)在抗癌药物耐药性中的作用的分子机制及其对临床实践的意义。
Crit Rev Oncol Hematol. 2012 Feb;81(2):103-22. doi: 10.1016/j.critrevonc.2011.03.010. Epub 2011 May 5.
6
The role of incoherent microRNA-mediated feedforward loops in noise buffering.非相干 microRNA 介导的前馈回路在噪声缓冲中的作用。
PLoS Comput Biol. 2011 Mar;7(3):e1001101. doi: 10.1371/journal.pcbi.1001101. Epub 2011 Mar 10.
7
Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.用于胰腺癌化疗敏感性和耐药性的表观遗传标记物——综述
Int J Cancer. 2011 Sep 1;129(5):1031-41. doi: 10.1002/ijc.26078. Epub 2011 Jun 18.
8
MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia.微小 RNA-193a 抑制 c-kit 表达,并作为急性髓系白血病中被甲基化沉默的肿瘤抑制因子发挥作用。
Oncogene. 2011 Aug 4;30(31):3416-28. doi: 10.1038/onc.2011.62. Epub 2011 Mar 14.
9
MicroRNAs and epigenetics.MicroRNAs 和表观遗传学。
FEBS J. 2011 May;278(10):1598-609. doi: 10.1111/j.1742-4658.2011.08089.x. Epub 2011 Mar 30.
10
Network perspectives on HDM2 inhibitor chemotherapy combinations.网络视角下的 HDM2 抑制剂化疗联合方案。
Curr Pharm Des. 2011;17(6):640-52. doi: 10.2174/138161211795222612.

胰腺癌中 miRNA 的异常表观遗传学修饰:系统生物学视角。

Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective.

机构信息

Department of Pathology & Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.

出版信息

Epigenomics. 2011 Dec;3(6):747-59. doi: 10.2217/epi.11.97.

DOI:10.2217/epi.11.97
PMID:22126293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3243906/
Abstract

Pancreatic cancer (PC) is a complex disease harboring a myriad of genetic and epigenetic changes. The dismal survival of patients diagnosed with PC is in part due to de novo and acquired resistance to conventional therapeutics, resulting from deregulated signaling including aberrant expression of small nc miRNAs. Emerging research in this area has lead to the identification and characterization of deregulated miRNAs, which have generated a renewed interest and hope in that novel targeting of miRNAs may lead to a better clinical outcome for patients diagnosed with PC. However, recent evidence suggests that miRNAs are also under a highly coordinated system of epigenetic regulation emphasizing the fact that the design of miRNAs as targeted therapy may not be as simple as originally anticipated. For a successful miRNA-based therapeutic regimen, a holistic integrated approach may be required to take into account because of these emerging epigenetic regulatory mechanisms. In this article, we will discuss miRNA epigenetics, it's significance in PC and the use of a systems science to identify these aberrant epigenetically groomed miRNAs, and we believe that such knowledge would likely benefit further research to realize the dream of miRNA-based targeted therapy for human malignancies.

摘要

胰腺癌(PC)是一种复杂的疾病,存在着无数的遗传和表观遗传变化。新诊断的 PC 患者的生存率令人沮丧,部分原因是由于信号失调,包括异常表达的小 nc miRNA,导致对常规治疗的新出现和获得性耐药。这一领域的新兴研究导致了失调 miRNA 的鉴定和特征描述,这为新的 miRNA 靶向治疗提供了新的兴趣和希望,可能为新诊断的 PC 患者带来更好的临床结果。然而,最近的证据表明,miRNA 也受到高度协调的表观遗传调控系统的控制,这强调了 miRNA 作为靶向治疗的设计可能并不像最初预期的那样简单。为了成功实施 miRNA 为基础的治疗方案,可能需要采用整体综合的方法,因为这些新兴的表观遗传调控机制。在本文中,我们将讨论 miRNA 的表观遗传学,它在 PC 中的意义,以及使用系统科学来识别这些异常的表观遗传修饰的 miRNA,我们相信这些知识可能会有助于进一步的研究,以实现 miRNA 为基础的针对人类恶性肿瘤的靶向治疗的梦想。